Banoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. It has been shown to work synergistically with fractionated radiation... Banoxantrone was also efficacious in tumour models when administered in combination with either cisplatin or chemoradiation.
- Mechanism
- Curator reviewed
Banoxantrone (formally known as AQ4N) is preferentially and irreversibly converted to AQ4, its cytotoxic form, in hypoxic tumour cells where it remains localised. When the surrounding oxygenated cells are killed by radiotherapy or chemotherapy bringing these AQ4-containing quiescent cells closer to the oxygen source, they become reoxygenated, attempt to resume replication and, in this state, are killed by AQ4 through potent DNA intercalation and topoisomerase II inhibition.
- Primary indication
- For the treatment of various forms of cancer.Curator reviewed
- Formula / weight
- C22H28N4O6 · 444.488 g/mol (avg)
- Code names
- AQ 4N
Resolves to
YZBAXVICWUUHGG-UHFFFAOYSA-NSMILESC[N+](C)([O-])CCNC1=CC=C(NCC[N+](C)(C)[O-])C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=OWhat you can answer from here — as of January 29, 2025
Which drugs share a target with Banoxantrone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account